

Increasing the quality of life in NSCLC patients by obdivo and taxoter with hyperthermia

S Badzgaradze*, Kh Shotadze, M Jhorjholiani and A Saldadze

S Badzgaradze*, Kh Shotadze, M Jhorjholiani and A Saldadze

Abstract

Topicality: Treatment of oncological patients and getting clinical remission is an unfortunate topic even for the 21st century; despite the correctly selected therapy, which gives minimal risks of complications because of the chemo sensitive tests, there are important problems connected with the quality of life of patients and naturally we ask questions to ourselves: How could we manage to increase the quality of life in oncological patients on the 3rd and 4th levels and decrease the number of the side effects that accompany Ch/therapy and R/therapy procedures.

Aim: The aim of the study was the patient with a 55-year diagnosis: NSCLC Thigh bone MTS, 3rd stage; R /therapy and 4 Courses CH /therapy; ECOG-2. Clinical remission was not achieved; Symptoms of progression of the hip fracture were strengthened, and the institution was addressed with the aforementioned history.

Methods and Materials: For the patient was selected CH/courses with hyperthermia and target therapy, we use Docetaxel 80 mg / m2 and oblivion recommended to strengthen the course effectiveness, weaken toxicity and to improve the quality of life recommended for the treatment CH/therapy + target therapy with hyperthermia and hypoglycaemia; For this procedure, a hyperthermic camera was installed, where the procedure is carried out at 43-48 degrees Celsius, and we have a sugar content of 25-30000 per one 40-45 mm / l in the bloodstream

Results: Only 2 courses were conducted with the patient with a CH/therapy and target therapy with hyperthermia.

Conclusion: So, we managed to get maximal results through high-tech hyperthermia Chemotherapy, patient's clinical remission and this was without any side effects. Increasing the quality of life, we recommend giving a hyperthermia chemotherapy and target therapy in oncological patients at 3rd and 4th stage, which is a firm guarantee of increasing their quality of life.

Biography

S Badzgaradze is a Founder of Georgia - Swiss Medical Training Center "MMC" In the year 2011-2012. She graduated from Institute of Critical Care Medicine - Faculty of Medicine, Tbilisi Medical State University. She received her Ph.D degree from Gr. Robakidze Georgian - American University. She is a Member of the International Association of European Oncology (ESMO) in 2013. Her research projects focus on the Diagnosis and treatment of anemia during the

hepatitis-B, B and Bio-compatible drug mimotycin synthesis and use. She gave her presence in ESMO congress 2019 and 37th Conference of the International Clinical Hyperthermia Society.

Abstract Citation: S Badzgaradze, Increasing the quality of life in NSCLC patients by obdivo and taxoter with hyperthermia, Cancer Summit 2020, 3rd Global Expo on Cancer and Oncology Research, July 30, 2020, Page 03

Conference URL: <https://cancersummit.alliedacademies.com/>



Speaker photo

***Corresponding author:** S Badzgaradze, Medical Center "SAROV", Georgia.

Received February 09, 2021; **Accepted** February 21, 2021; **Published** February 27, 2021

Citation: Badzgaradze S, Shotadze KH, Jhorjholiani M, Saldadze A (2021) ERK signaling-mediated molecules in the progression of liver cirrhosis and hepatocellular carcinoma. J Entrepren Organiz Manag 10: e119.

Copyright: © 2021 Badzgaradze S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.